NSAIDs are currently recommended as first-line therapy but pose the risk of serious adverse effects.
Identifying populations at risk may provide opportunities for primary prevention.
The gout-dementia connection, daily medication reminders, and the impact of interleukin-1β inhibition on gout attacks.
Hyperuricemia remains the leading risk factor, but the runners-up may surprise you.
Here: the latest evidence on the effects of febuxostat, allopurinol, and statins on CV mortality in patients with gout.
Despite its antioxidant properties, uric acid may not be as neuroprotective as previously thought.
Recent findings call into question the safety of long-term febuxostat therapy in patients with cardiovascular disease.
Should urate-lowering therapy be continued during an acute gout attack? Which antihypertensive has mild uricosuric effects? Test yourself with these questions and more.
Among the highlights of 3 recent studies: insights into hormonal risk factors for rheumatoid arthritis.
Highlights of 3 recent studies that can affect your practice: a novel procedure for knee pain, cardiovascular risk in RA, and febuxostat in early gout.